Accuragen, a US-based cancer detection company and graduate from Stanford University’s StartX accelerator, has raised $40m in its latest round from investors including the accelerator, according to the Silicon Valley Business Journal.
StartX participated alongside Junson Capital, Decheng Capital, DT Capital and Nan Fung Capital. Temasek, an investment firm owned by the government of Singapore, also supplied cash.
Accuragen has developed a cancer detection test that looks for cancer mutations circulating in cell-free DNA in the blood.
StartX supports entrepreneurs from Stanford University. It provides a network, mentoring, education and resources to the companies taking part and does not take any equity.
Accuragen has offices in Silicon Valley and Shanghai.
In 2015, the company raised $6.9m in a series A round provided by Decheng Capital and Denlux Capital, as well as funds operated by Yifang Group Holdings and WS Investment.
